# Phase B Implementation Plan Independent Review

**Date:** 2026-11-08  
**Result:** PASS — no material planning blocker remains  
**Scope:** A0, Foundation, Plans 2–6, plan index, traceability, dependency/gate matrix, review matrix, and pending Product Owner approval record

## Review method

- Main-agent line-by-line review against the approved System/Architecture Design, Project Governance Design, and Phase B approval design.
- Independent whole-set builder review of A0 and Foundation at execution-detail level.
- Independent specialist audit of Plans 2–3 and their cross-plan interfaces.
- Independent specialist audit of Plans 4–6 and their cross-plan interfaces.
- Re-review after every material correction; final builder result was `PASS`.

## Material corrections closed

- Aligned A0 with the authoritative late-arrival boundary: priority is released at exactly T+15:00.
- Made the A0 archive/docs-only handoff executable with committed review evidence and exact restore paths.
- Added full A0 rule/store interfaces and test-first doctor-leave UI coverage.
- Made Foundation Task 1 preserve root pnpm release/build policy and deliberately retire nested workspace metadata.
- Replaced broad Foundation auth/deployment instructions with exact files, interfaces, red/green tests, and commit boundaries.
- Defined API-backed one-time OIDC state/nonce/PKCE attempts, opaque browser cookies, server-side token storage, refresh rotation, and complete environment contracts.
- Defined zero-cost fake-staging access using WireGuard for remote admin, per-device mTLS at Caddy, and Caddy-to-API mTLS; IP ranges classify context only after certificate authentication.
- Required fake Keycloak staging to enforce TOTP/LoA 2 and validate `acr=2` rather than silently weakening MFA.
- Added exact node/container/PostgreSQL exporters and pgBackRest continuous-archive/restore configuration.
- Removed the Plan 3/Plan 4 treatment-course dependency cycle and defined exact commercial/migration contexts.
- Made medication reservation precede payment/receipt and fully defined receipt replacement without refund or transaction reversal.
- Added expiry/near-expiry policy, paper/image migration evidence, synthetic-only rehearsal, and external technical/compliance preflight gates.

## Verification evidence

- All Markdown internal links resolved.
- No `TODO`, `TBD`, `FIXME`, obsolete app paths, old ADR collision, obsolete medicine state, or unresolved Foundation wildcard remained in the reviewed baseline.
- Plan task counts: A0 7; Foundation 9; Appointments 7; Clinical 8; Commercial 7; Inventory 8; Compliance/Go-live 8.
- `admin-skinlab` remained clean on `dev`; no product code, repository migration, dependency install, commit, push, or infrastructure deployment was performed.
- At independent-review completion, `docs/governance/PHASE_B_PLAN_APPROVAL.md` was pending with all Product Owner checkboxes unchecked; it was subsequently approved by the Product Owner on 2026-11-08.

## Approval boundary

This review recommends:

- A0 and Foundation: approve for execution in the stated fake-data scope.
- Plans 2–6: approve roadmap scope/order only, with just-in-time revalidation.
- Real patient data, production, replacement of paper authority, and closure of external technical/compliance gates: not approved.

The Product Owner subsequently approved and signed the baseline on 2026-11-08, satisfying this review condition. A separate execution hold initially prevented implementation; it was later lifted for Foundation Task 1 on 2026-11-09.
